Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.

W. W. Koontz, N. M. Heney, M. S. Soloway, L. Kluskens, T. A. Hazra, D. L. Trump, B. Barton

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa. A total of 117 patients with residual superficial transitional cell bladder cancer (Ta, T1, Tis) who had previously failed on intravesical thiotepa were treated with 40 mg of mitomycin instilled intravesically weekly for eight weeks. Four to six weeks after the last treatment, tumor response was evaluated by cystoscopy, biopsy of the site of the index lesion, and cytology. In 57 patients (48.7%), visible tumor had been ablated. Results of cystoscopy, biopsy, and cytology were negative in 32 (27.4%) patients. Eleven patients (9.4%) had no visible tumor and negative cytology unconfirmed by biopsy. In 14 patients (12%) who had complete destruction of the tumor at cystoscopy, and biopsy specimen was negative for tumor, cytology was positive, indicating a partial response. Six patients (5.1%) withdrew from the study before the first evaluation because of local toxicity (cystitis).

Original languageEnglish
Pages (from-to)30-31
Number of pages2
JournalUrology
Volume26
Issue number4 Suppl
StatePublished - Oct 1 1985

Fingerprint

Thiotepa
Mitomycin
Urinary Bladder Neoplasms
Cystoscopy
Cell Biology
Biopsy
Neoplasms
Cystitis

ASJC Scopus subject areas

  • Urology

Cite this

Koontz, W. W., Heney, N. M., Soloway, M. S., Kluskens, L., Hazra, T. A., Trump, D. L., & Barton, B. (1985). Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. Urology, 26(4 Suppl), 30-31.

Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. / Koontz, W. W.; Heney, N. M.; Soloway, M. S.; Kluskens, L.; Hazra, T. A.; Trump, D. L.; Barton, B.

In: Urology, Vol. 26, No. 4 Suppl, 01.10.1985, p. 30-31.

Research output: Contribution to journalArticle

Koontz, WW, Heney, NM, Soloway, MS, Kluskens, L, Hazra, TA, Trump, DL & Barton, B 1985, 'Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.', Urology, vol. 26, no. 4 Suppl, pp. 30-31.
Koontz WW, Heney NM, Soloway MS, Kluskens L, Hazra TA, Trump DL et al. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. Urology. 1985 Oct 1;26(4 Suppl):30-31.
Koontz, W. W. ; Heney, N. M. ; Soloway, M. S. ; Kluskens, L. ; Hazra, T. A. ; Trump, D. L. ; Barton, B. / Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. In: Urology. 1985 ; Vol. 26, No. 4 Suppl. pp. 30-31.
@article{521483bdf4334fd0b433c7cb3b6aa096,
title = "Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.",
abstract = "The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa. A total of 117 patients with residual superficial transitional cell bladder cancer (Ta, T1, Tis) who had previously failed on intravesical thiotepa were treated with 40 mg of mitomycin instilled intravesically weekly for eight weeks. Four to six weeks after the last treatment, tumor response was evaluated by cystoscopy, biopsy of the site of the index lesion, and cytology. In 57 patients (48.7{\%}), visible tumor had been ablated. Results of cystoscopy, biopsy, and cytology were negative in 32 (27.4{\%}) patients. Eleven patients (9.4{\%}) had no visible tumor and negative cytology unconfirmed by biopsy. In 14 patients (12{\%}) who had complete destruction of the tumor at cystoscopy, and biopsy specimen was negative for tumor, cytology was positive, indicating a partial response. Six patients (5.1{\%}) withdrew from the study before the first evaluation because of local toxicity (cystitis).",
author = "Koontz, {W. W.} and Heney, {N. M.} and Soloway, {M. S.} and L. Kluskens and Hazra, {T. A.} and Trump, {D. L.} and B. Barton",
year = "1985",
month = "10",
day = "1",
language = "English",
volume = "26",
pages = "30--31",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4 Suppl",

}

TY - JOUR

T1 - Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.

AU - Koontz, W. W.

AU - Heney, N. M.

AU - Soloway, M. S.

AU - Kluskens, L.

AU - Hazra, T. A.

AU - Trump, D. L.

AU - Barton, B.

PY - 1985/10/1

Y1 - 1985/10/1

N2 - The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa. A total of 117 patients with residual superficial transitional cell bladder cancer (Ta, T1, Tis) who had previously failed on intravesical thiotepa were treated with 40 mg of mitomycin instilled intravesically weekly for eight weeks. Four to six weeks after the last treatment, tumor response was evaluated by cystoscopy, biopsy of the site of the index lesion, and cytology. In 57 patients (48.7%), visible tumor had been ablated. Results of cystoscopy, biopsy, and cytology were negative in 32 (27.4%) patients. Eleven patients (9.4%) had no visible tumor and negative cytology unconfirmed by biopsy. In 14 patients (12%) who had complete destruction of the tumor at cystoscopy, and biopsy specimen was negative for tumor, cytology was positive, indicating a partial response. Six patients (5.1%) withdrew from the study before the first evaluation because of local toxicity (cystitis).

AB - The National Bladder Cancer Group undertook a study to determine the effectiveness and toxicity of mitomycin in patients who failed on thiotepa. A total of 117 patients with residual superficial transitional cell bladder cancer (Ta, T1, Tis) who had previously failed on intravesical thiotepa were treated with 40 mg of mitomycin instilled intravesically weekly for eight weeks. Four to six weeks after the last treatment, tumor response was evaluated by cystoscopy, biopsy of the site of the index lesion, and cytology. In 57 patients (48.7%), visible tumor had been ablated. Results of cystoscopy, biopsy, and cytology were negative in 32 (27.4%) patients. Eleven patients (9.4%) had no visible tumor and negative cytology unconfirmed by biopsy. In 14 patients (12%) who had complete destruction of the tumor at cystoscopy, and biopsy specimen was negative for tumor, cytology was positive, indicating a partial response. Six patients (5.1%) withdrew from the study before the first evaluation because of local toxicity (cystitis).

UR - http://www.scopus.com/inward/record.url?scp=0022134197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022134197&partnerID=8YFLogxK

M3 - Article

C2 - 3931326

AN - SCOPUS:0022134197

VL - 26

SP - 30

EP - 31

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4 Suppl

ER -